Your browser doesn't support javascript.
loading
RAS and BRAF mutations in cell-free DNA are predictive for outcome of cetuximab monotherapy in patients with tissue-tested RAS wild-type advanced colorectal cancer.
van Helden, Erik J; Angus, Lindsay; Menke-van der Houven van Oordt, C Willemien; Heideman, Daniëlle A M; Boon, Eline; van Es, Suzanne C; Radema, Sandra A; van Herpen, Carla M L; de Groot, Derk Jan A; de Vries, Elisabeth G E; Jansen, Maurice P H M; Sleijfer, Stefan; Verheul, Henk M W.
Afiliación
  • van Helden EJ; Department of Medical Oncology, Cancer Center Amsterdam, Amsterdam UMC, Vrije Universiteit Amsterdam, The Netherlands.
  • Angus L; Department of Medical Oncology, Erasmus MC Cancer Institute, Erasmus University Medical Center, Rotterdam, The Netherlands.
  • Menke-van der Houven van Oordt CW; Department of Medical Oncology, Cancer Center Amsterdam, Amsterdam UMC, Vrije Universiteit Amsterdam, The Netherlands.
  • Heideman DAM; Department of Pathology, Cancer Center Amsterdam, Amsterdam UMC, Vrije Universiteit Amsterdam, The Netherlands.
  • Boon E; Department of Medical Oncology, Radboud University Medical Center, Nijmegen, The Netherlands.
  • van Es SC; Department of Medical Oncology, University Medical Center Groningen, The Netherlands.
  • Radema SA; Department of Medical Oncology, Radboud University Medical Center, Nijmegen, The Netherlands.
  • van Herpen CML; Department of Medical Oncology, Radboud University Medical Center, Nijmegen, The Netherlands.
  • de Groot DJA; Department of Medical Oncology, University Medical Center Groningen, The Netherlands.
  • de Vries EGE; Department of Medical Oncology, University Medical Center Groningen, The Netherlands.
  • Jansen MPHM; Department of Medical Oncology, Erasmus MC Cancer Institute, Erasmus University Medical Center, Rotterdam, The Netherlands.
  • Sleijfer S; Department of Medical Oncology, Erasmus MC Cancer Institute, Erasmus University Medical Center, Rotterdam, The Netherlands.
  • Verheul HMW; Department of Medical Oncology, Cancer Center Amsterdam, Amsterdam UMC, Vrije Universiteit Amsterdam, The Netherlands.
Mol Oncol ; 13(11): 2361-2374, 2019 11.
Article en En | MEDLINE | ID: mdl-31350822
Asunto(s)
Palabras clave
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Neoplasias Colorrectales / Proteínas ras / Proteínas Proto-Oncogénicas B-raf / Cetuximab / ADN Tumoral Circulante / Mutación Tipo de estudio: Clinical_trials / Prognostic_studies / Risk_factors_studies Límite: Aged / Aged80 / Female / Humans / Male / Middle aged Idioma: En Revista: Mol Oncol Asunto de la revista: BIOLOGIA MOLECULAR / NEOPLASIAS Año: 2019 Tipo del documento: Article País de afiliación: Países Bajos Pais de publicación: Estados Unidos
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Neoplasias Colorrectales / Proteínas ras / Proteínas Proto-Oncogénicas B-raf / Cetuximab / ADN Tumoral Circulante / Mutación Tipo de estudio: Clinical_trials / Prognostic_studies / Risk_factors_studies Límite: Aged / Aged80 / Female / Humans / Male / Middle aged Idioma: En Revista: Mol Oncol Asunto de la revista: BIOLOGIA MOLECULAR / NEOPLASIAS Año: 2019 Tipo del documento: Article País de afiliación: Países Bajos Pais de publicación: Estados Unidos